Ridaforolimus (Deforolimus AP23573) BEZ235 SF1126 XL418 XL765 XL147 Everolimus (RAD001) PX-866 XL281 Perifosine XL228 RDEA119 GDC-0941 bismesylate PF-04691502 GDC-0973 Sirolimus (Rapamune) GDC-0980 Temsirolimus (Torisel, CCI-779) Selumetinib (AZD6244)

SF1126

SF1126, under development by Semafore Pharmaceuticals, is an inhibitor of the PI3K pathway.  This pathway is clearly relevant to GIST.  For information at the manufacturer's site click here.

According to the Semafore news release, SF1126 is available in a Phase I trial being conducted at these locations: 

• Virginia Piper Cancer Center, Scottsdale
  contact patient care coordinator, Joyce Ingold RN MSN OCN
  TGen Clinical Research Services
  Patient Care Coordinator
  10460 N. 92nd Street, Suite 206
  Scottsdale, AZ 85258
  Office 480-323-1339
  Fax 480-323-1259
  jingold@shc.org
• Indiana University Cancer Center

The trial name is "A Phase I Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study in SF1126, a PI Kinase (PI3K) Inhibitor, Given Twice Weekly by IV Infusion to Patients With Advanced or Metastatic Tumors."  It is not yet listed on the clinicaltrials.gov website.

For more information please contact TGen Clinical Research Services.